CYP3A Metabolizer Status Prediction via Genotyping Algorithms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective tools for predicting drug metabolism variability due to inter-individual differences in CYP3A4 and CYP3A5 enzyme activity, leading to therapeutic failures or adverse effects from drug interactions.
Innovation Solution
A computer-assisted method involving genotyping assays for CYP3A4 and CYP3A5 genes, using specific SNPs to determine metabolizer status through algorithms that analyze genotype data and metabolic impacts of drugs, generating reports for predicting drug efficacy and potential adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genotyping assays for CYP3A4 and CYP3A5 are conducted to predict metabolizer status, then measurement precision of drug metabolism prediction is improved, but device complexity and ease of operation worsen due to multiple genetic markers and algorithmic analysis requirements
Solution Approach 1:
The patent segments the complex CYP3A metabolism prediction into distinct genetic markers (CYP3A4*22 at rs35599367, CYP3A5*3 at rs776746, CYP3A5*7 at rs41303343) that can be tested independently through separate genotyping assays. This segmentation allows each marker to be analyzed individually while contributing to the overall metabolizer status prediction, reducing the complexity of analyzing the entire system at once.
Solution Approach 2:
The patent introduces computer-assisted algorithms as intermediaries that process genotyping data and apply decision tables (Table 2a and 2b) to determine metabolizer status. These algorithms act as mediators between the raw genetic data and the clinical interpretation, automatically calculating contribution ratios and predicting drug metabolism outcomes without requiring manual analysis of multiple genetic markers.
2Reliability
If multiple genetic markers are analyzed through computer algorithms, then reliability of drug metabolism prediction is improved, but loss of time in data processing and analysis increases
Solution Approach 1:
The patent establishes predetermined decision tables (Table 2a and 2b) and contribution ratio formulas that encode the relationships between genetic markers and metabolizer status in advance. These pre-programmed rules allow the computer algorithm to rapidly process genotyping data by simply applying stored logic rather than performing complex real-time analysis, significantly reducing processing time while maintaining prediction reliability.
3Manufacturing precision
If contribution ratios of CYP3A4 and CYP3A5 are calculated using predetermined formulas, then manufacturing precision of metabolism prediction model is improved, but ease of operation deteriorates due to complex mathematical calculations
Solution Approach 1:
The patent implements self-service through automated computer algorithms that perform all contribution ratio calculations independently. The system automatically inputs genotyping data, applies the predetermined formulas (such as Equation 1: CR3A4 + CR3A5 = 1), and generates metabolizer status predictions without requiring manual mathematical operations by clinicians. This eliminates the operational burden while maintaining precise calculation-based predictions.
Data Source
AI summary
The present invention provides methods and materials useful for determining metabolizer status. Embodiments of the present invention provide an approach using a genotyping panel and integration of genotypes of CYP3A4 and CYP3A5 to assess CYP3A metabolizer status, applicable to all CYP3A substrates, including approximately 40% of all drugs. Algorithms for CYP3A metabolizer status are described. Where the contribution ratios of CYP3A4 and CYP3A5 to overall drug levels or drug effects are known, the algorithm can be used to calculate optimal dosing. Where the contributory ratios to overall drug effects are not available, the contributory ratios can be calculated with use of the genotypes for use in drug development. Embodiments of the present invention can be used in optimizing drug treatments, selecting dose, designing therapeutics, and predicting efficacy.